Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 8Completed 4Terminated 2Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 6Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2Lymphoma, Follicular 2Lymphoma 2Hodgkin Disease 2Ganglioneuroblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 3naxitamab 2fludarabine phosphate 2fludarabine 2dinutuximab 2Topotecan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Colony-Stimulating Factors 2sargramostim 1iberdomide 1eliglustat 1Vorinostat 1Thiotepa 1Tacrolimus 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Isotretinoin 1Cyclosporine 1Busulfan 1Biopsy 1Antilymphocyte Serum 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neuroblastoma × Magnetic Resonance Spectroscopy × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡